Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection

Andrea Menicucci, Allen Jankeel, Heinz Feldmann, Andrea Marzi, Ilhem Messaoudi

mBio · 2019 · 56 citations · 25 references

DOIFull text

Open access

Concepts

Abstract

Ebola virus (EBOV) is the causative agent of Ebola virus disease (EVD), a deadly disease and major public health threat worldwide. A safe and highly efficacious vesicular stomatitis virus-based vaccine against EBOV is the only platform that has successfully completed phase III clinical trials and has been used in recent and ongoing outbreaks. Earlier studies showed that antibodies are the main mode of protection when this vaccine is administered 28 days before EBOV challenge. Recently, we showed this vaccine can provide protection when administered as early as 3 days before challenge and before antibodies are detected. This study seeks to identify the mechanisms of rapid protection, which in turn will pave the way for improved vaccines and therapeutics. Additionally, this study provides insight into host gene expression signatures that could provide early biomarkers to identify infected individuals who are at highest risk of poor outcomes.

References

25